Navigation Links
Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Date:6/11/2008

infusion daily for five days of a 21-day cycle in patients with advanced pancreatic cancer who have progressed on gemcitabine or a gemcitabine-containing regimen.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.

Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to the therapeutic and commercial potential of PX-12; future clinical development plans; the details of clinical trials; and the anticipated future size of the market for PX-12. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, and the safety and efficacy of PX-12. There can be no guarantee that the results of earlier trials will be predictive of
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon to receive milestone payment
2. Oncothyreon Reports First Quarter 2008 Financial Results
3. Oncothyreon files investigational new drug application for PX-866 oncology compound
4. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
5. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
6. Oncothyreon announces effectiveness of shelf registration statement
7. Oncothyreon announces issuance of patent for PX-867
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon reports full year and fourth quarter 2007 financial results
10. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
11. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management ... Product Strategy. In this role, Michelle will work with current ... in the development of iLab products. Her main goal will ... to the scientific community by offering the most advanced, user-friendly, ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... In a video interview, new CEO,Andrew Witty comments on ... strategic vision for the business., The ... diversified global business - Deliver more products of value ... and vodcast are available now on, http://www.cantos.com . It,s free ...
... 23 Duska Therapeutics,Inc. (OTC Bulletin Board: DSKA) ... a synopsis of a proposed Phase 3 clinical ... Food and Drug Administration,s (the,"FDA") Division of Cardiovascular ... with the FDA, including a face-to-face,meeting held on ...
... Next generation design reduces the amount of retraction needed for surgical ... ... July 23 Pioneer Surgical Technology,today announces the market availability of ... optimize,anterior cervical fusion procedures while addressing the clinical needs of,anterior cervical ...
Cached Biology Technology:Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 3Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 4Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System 2
(Date:4/18/2014)... predicted to reach 9 billion by 2050 will ... human-altered landscapes such as farmland, according to Stanford ... supports it might be an increasingly scarce commodity ... the land surface is directly affected by humans ... such as climate change. But what if altered ...
(Date:4/18/2014)... comet impacts can cause widespread ecological havoc, killing off ... But new research from Brown University shows that impacts ... the time of an impact. , A research team ... of leaves and preserved organic compounds lodged inside glass ... material could provide a snapshot of environmental conditions at ...
(Date:4/17/2014)... , Respiratory syncytial virus (RSV) is a ... life-threating illness in very young and elderly populations. ... enters host cells through the fusion protein RSV ... interfering peptides that prevent bundle formation limit RSV ... susceptible to degradation. In this issue of the ...
Breaking Biology News(10 mins):Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6
... and Wireless ... Solutions for Emergency Responders, WALL, N.J., Oct. 15 ... biometric,identification and wireless public safety solutions, today announced that,it will ... of Chiefs of Police (IACP) Conference and,Exposition, October 15-17 at ...
... early in adulthood, aging begins to slow the mind,s growth ... suggests a Princeton University study on the brains of adult ... soon after marmoset monkeys reach adulthood, the rate at which ... animals, brains begins to decline. The hippocampus is associated with ...
... (AD) is a progressive neurodegenerative disorder characterized by ... amyloid plaques and neurofibrillary tangles. Neuronal and synaptic ... occur in specific brain areas involved in memory ... cerebral deposition of A" plays a seminal role ...
Cached Biology News:BIO-key International Showcasing Innovative Public Safety Solutions at 2007 IACP Conference 2BIO-key International Showcasing Innovative Public Safety Solutions at 2007 IACP Conference 3Brain cell growth diminishes long before old age strikes, animal study shows 2Paradigm shift in Alzheimers's research: new treatments 2Paradigm shift in Alzheimers's research: new treatments 3Paradigm shift in Alzheimers's research: new treatments 4
Human HVEM/TNFRSF14 Allophycocyanin MAb (Clone 94801)...
Enodgenous alkaline phosphotase inhibitor. Levamisole solution is supplied in concentrated form (20x). The final concentration of levamisole in the substrate solution will be 1 mM....
X-gal,1g...
...
Biology Products: